All Updates

All Updates

icon
Filter
Funding
Latus Bio Inc. raises USD 54 million in Series A funding
Cell & Gene Therapy
May 3, 2024
This week:
Product updates
Nintendo ventures into MMOs with new Switch Online game playtest
Metaverse Experience Platforms
Yesterday
Product updates
HP releases texture library for 3D printing with CoreTechnologie 4D Additive
Additive Manufacturing
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Smart Factory
Oct 21, 2024
Product updates
xAI launches API for third-party developers to access Grok models
Foundation Models
Oct 21, 2024
Partnerships
Nava Benefits partners with OpenAI to launch AI-powered benefits assistant
Foundation Models
Oct 21, 2024
Product updates
IBM releases Granite 3.0 AI models for enterprise use
Foundation Models
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Foundation Models
Oct 21, 2024
M&A
Inflection AI acquires Boundaryless for undisclosed sum to accelerate enterprise AI deployments
Foundation Models
Oct 21, 2024
Industry news
News Corp sues Perplexity AI for alleged copyright infringement
Generative AI Applications
Oct 21, 2024
Product updates
Haiper debuts new video generation model
Generative AI Applications
Oct 21, 2024
Cell & Gene Therapy

Cell & Gene Therapy

May 3, 2024

Latus Bio Inc. raises USD 54 million in Series A funding

Funding

  • Gene therapy company Latus Bio Inc. has secured USD 54 million in a Series A funding round led by 8VC and DCVC Bio, with participation from Samsung Life Science Fund and other undisclosed investors. The Samsung Life Science Fund is backed by Samsung Biologics Co., Samsung Bioepis Co., and Samsung C&T Corp.

  • Latus Bio intends to use the funding to expedite the development of its gene therapies for CLN2 disease and Huntington’s disease. The company aims to begin human trials of the therapy for the CLN2 disease by 2025.

  • The Philadelphia-based company develops gene therapy solutions for central nervous system (CNS) disorders. Leveraging advanced adeno-associated virus (AAV) capsids, the company aims to enhance the precision and efficacy of gene delivery, which addresses the common challenges of traditional gene therapies, such as limited potency, off-target effects, and scalability issues. Its platform involves high-throughput screening of millions of novel capsid variants to identify those with the best tissue and cellular targeting capabilities, thereby minimizing potential immunogenicity and toxicity.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.